BioNtech to Provide UK up to 10,000 Personalized mRNA Cancer Immunotherapies by 2030

 

• Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in the UK
• BioNTech aims to design and roll out randomized clinical trials with registrational potential for the Company’s personalized mRNA cancer immunotherapies in the UK
• Accelerated clinical trial recruitment with first patient to be enrolled in a trial as part of this collaboration in H2 2023
• Set-up of an R&D hub in Cambridge (UK) with the aim to employ more than 70 highly skilled scientists with the first employees commencing work in Q1 2023

https://www.biospace.com/article/releases/biontech-announces-strategic-partnership-with-uk-government-to-provide-up-to-10-000-patients-with-personalized-mrna-cancer-immunotherapies-by-2030/